Key terms
About ONCY
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ONCY news
Mar 09
12:25pm ET
Buy Rating Affirmed for Oncolytics Biotech Amidst Promising Pipeline and Advancements in Cancer Treatment Trials
Mar 08
4:25pm ET
Buy Rating Affirmed on Oncolytics Biotech Amid Progress and Strategic Clinical Trials
Mar 08
12:35pm ET
Maintaining Buy Rating on ONCY Amidst Promising Clinical Advancements and Partnership Potential
Mar 08
7:27am ET
Oncolytics Biotech (ONCY) Gets a Buy from RBC Capital
Mar 07
4:38pm ET
Oncolytics Biotech Shows Promising Cancer Drug Progress
Mar 05
7:50am ET
Oncolytics Biotech Expands Pancreatic Cancer Study
Feb 28
7:40am ET
Oncolytics Biotech Spotlights at NeauxCancer Conference
Feb 14
9:55am ET
Reiterating Buy Rating: Expanding Potential of Pelareorep in Oncolytics Biotech’s Pipeline
Feb 14
7:09am ET
Oncolytics expands enrollment for GOBLET study evaluating pelareorep
Jan 22
1:47pm ET
Buy Rating for Oncolytics Biotech Amidst Promising Trials and Anticipated Partnerships
Jan 04
10:30am ET
Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY), Rhythm Pharmaceuticals (RYTM) and Rigel (RIGL)
Jan 04
7:08am ET
Oncolytics sees cash balance sufficient for over 12 month runway
No recent news articles are available for ONCY
ONCY Financials
Key terms
Ad Feedback
ONCY Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ONCY Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range